Indolent Lymphomas (Follicular Lymphoma)

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

Type: Multi-centre, randomised, phase III, study
Eligibility: A comparision of first-line R-CVP versus R-FC in elderly patients with Folicular Lymphoma
Study details: FL predominantly affects the elderly, yet the optimum treatment for older patients with disease has not been defined. The present study aims to address this question by compairing the drug combination that is currently considered the gold-standard (R-CVP) with a newer cimbination (R-FC) that might be more effective without being significally more toxic. In order to take into accoount the blance between efficacy and toxicitly, a dual primary endpoint has been employed: progression-free survival and toxicity in the form of grade 3-4 infection.